Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice Supplementary material

People with relapsing/remitting multiple sclerosis (PwRRMS) are treated with
drugs, for example, glatiramer acetate (GA) or IFN-β. We checked if these drugs improved quality of life
(QoL) in PwRRMS in Greece. QoL was measured by seven questionnaires, askingmany questions on aspects
of life. One survey showed significant improvements with GA treatment in almost half of the question
groups. Similar improvements in this survey were seen with GA in patients who had no other previous
treatments. No changes were seen in GA-treated PwRRMS who previously received IFN-β, or treated with
IFN-β alone. Slight improvements in fatigue and sexual satisfaction were seen. No QoL deteriorations were
seen in the other four questionnaires. Twelve months of GA treatment, but not IFN-β, improved certain
QoL parameters in treatment-naive PwRRMS.